title: Elements for Success in Managing Type 2 Diabetes With SGLT-2 Inhibitors: Overview of the Efficacy and Safety of SGLT-2 Inhibitors in Type 2 Diabetes Mellitus.
abstract: Since the approval of the first sodium-glucose cotransporter-2 (SGLT-2) inhibitor by the US Food and Drug Administration (FDA) in 2013, the SGLT-2 inhibitors have assumed key roles in the management of patients with type 2 diabetes mellitus (T2DM). This review covers the safety and efficacy of these agents when used in this patient population.
authors.affiliation: Executive Director and Co-founder, Diabetes Nation, High Lakes Health Care, St. Charles Hospital, Bend, OR, USA.
authors.forename: Eden M
authors.initials: EM
authors.lastname: Miller
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001786:Blood Glucose / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D018570:Risk Assessment; D051297:Sodium-Glucose Transporter 2 / Q000627:therapeutic use*; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014481:United States
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors